Avila Therapeutics, Inc. – Product Pipeline Review – H2 2011

Date: December 1, 2011
Pages: 50
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A04CBC6F9AEEN
Leaflet:

Download PDF Leaflet

Avila Therapeutics, Inc. - Product Pipeline Review - H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Avila Therapeutics, Inc. - Product Pipeline Review - H2 2011” provides data on the Avila Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Avila Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Avila Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Avila Therapeutics, Inc. - Brief Avila Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Avila Therapeutics, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Avila Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Avila Therapeutics, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Avila Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Avila Therapeutics, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Avila Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Avila Therapeutics, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Avila Therapeutics, Inc. and identify potential opportunities in those areas.
Avila Therapeutics, Inc. Snapshot
Avila Therapeutics, Inc. Overview
Key Information
Key Facts
Avila Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Avila Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Avila Therapeutics, Inc. – Pipeline Products Glance
Avila Therapeutics, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Avila Therapeutics, Inc. – Drug Profiles
AVL-181
AVL-192
AVL-291
CNX-1351
CNX-222
Avila Therapeutics, Inc. – Pipeline Analysis
Avila Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Avila Therapeutics, Inc. - Pipeline Products By Target
Avila Therapeutics, Inc. – Pipeline Products by Route of Administration
Avila Therapeutics, Inc. – Pipeline Products by Molecule Type
Avila Therapeutics, Inc. – Recent Pipeline Updates
Avila Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Company's Recent Developments
Avila Therapeutics, Inc., Recent Developments
Sep 30, 2010: Avila Initiates Phase I Clinical Study Of AVL-292 For Treatment Of B Cell Cancers And Autoimmune Diseases
Jun 23, 2011: Avila Presents Preclinical Data Of AVL-292 Demonstrating Suppression Of Autoimmune Disease Activity
Apr 16, 2010: Avila Presents Preclinical Data On AVL-181 For Hepatitis C Infection At EASL 2010 Meeting
Apr 16, 2010: Avila Presents Preclinical Data On AVL-192 For Hepatitis C Infection At EASL 2010 Meeting
Sep 14, 2011: Avila Completes Dosing Of First Patient Cohort In Phase Ib Clinical Study Of AVL-292 For Treatment Of B Cell Cancers
Jun 10, 2011: Avila Therapeutics Presents Positive Data On AVL-292 At 16th Congress Of European Hematology Association
Nov 08, 2011: Avila Therapeutics Presents Clinical And Preclinical Data On AVL-292 Showing Potential For Treatment Of Autoimmune Disease At 2011 American College Of Rheumatology Annual Scientific Meeting
Jun 08, 2011: Avila Signs Agreement With National Institute Of Allergy And Infectious Diseases
Apr 06, 2011: Avila Announces Positive Clinical Data For Btk Inhibitor, AVL-292, In Phase Ia Studies
Apr 05, 2011: Avila Presents Data on Novel PI3K-Alpha Inhibitor Designed as a Targeted Covalent Drug at American Association for Cancer Research Annual Meeting
Nov 02, 2010: Avila Reports New Preclinical Study Data On AVL-192
Financial Deals Landscape
Avila Therapeutics, Inc., Deals Summary
Avila Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Avila Therapeutics Secures $30 Million In Series B Financing Round
Avila Therapeutics Secures $5 Million In Venture Financing
Avila Therapeutics Secures $21 Million In Series A Financing
Partnerships
Clovis Oncology Enters Into Co-Development Agreement With Avila Therapeutics
Avila Therapeutics Enters Into Co-Development Agreement With The Leukemia & Lymphoma Society
Avila Therapeutics Enters Into Agreement With Novartis Venture Funds
Licensing Agreements
Avila Therapeutics Enters Into Licensing Agreement With Sanofi-aventis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Avila Therapeutics, Inc., Key Information
Avila Therapeutics, Inc., Key Facts
Avila Therapeutics, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Avila Therapeutics, Inc. – Pipeline by Stage of Development, H2 2011
Avila Therapeutics, Inc. – Monotherapy Products in Pipeline, H2 2011
Avila Therapeutics, Inc. – Pre-Clinical, H2 2011
Avila Therapeutics, Inc. - Pipeline By Therapeutic Class, H2 2011
Avila Therapeutics, Inc. - Pipeline By Target, H2 2011
Avila Therapeutics, Inc. – Pipeline By Route of Administration, H2 2011
Avila Therapeutics, Inc. – Pipeline By Molecule Type, H2 2011
Avila Therapeutics, Inc. – Recent Pipeline Updates, H2 2011
Avila Therapeutics, Inc., Deals Summary
Avila Therapeutics Secures $30 Million In Series B Financing Round
Avila Therapeutics Secures $5 Million In Venture Financing
Avila Therapeutics Secures $21 Million In Series A Financing
Clovis Oncology Enters Into Co-Development Agreement With Avila Therapeutics
Avila Therapeutics Enters Into Co-Development Agreement With The Leukemia & Lymphoma Society
Avila Therapeutics Enters Into Agreement With Novartis Venture Funds
Avila Therapeutics Enters Into Licensing Agreement With Sanofi-aventis

LIST OF FIGURES

Avila Therapeutics, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Avila Therapeutics, Inc. – Pipeline by Stage of Development, H2 2011
Avila Therapeutics, Inc. – Monotherapy Products in Pipeline, H2 2011
Avila Therapeutics, Inc. – Pipeline By Therapeutic Class, H2 2011
Avila Therapeutics, Inc. - Pipeline By Target, H2 2011

Ask Your Question

Avila Therapeutics, Inc. – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: